Novo Nordisk has announced plans to invest DKK 500 million ($82 million) to expand table production facilities at its site in Måløv, Denmark.

The facility currently manufactures products for oral diabetes treatment and will be expanded to ensure capacity for future production of these products. The project is expected to be completed in 2022.

The Måløv site includes the company’s largest research center with production facilities for both diabetes and biopharmaceutical products. The site produces the oral dosage form of semaglutide, a treatment for Type 2 diabetes. The site currently employs around 700 people.

Source: Novo Nordisk